Further launches of generic lenalidomide rivals to Celgene’s Revlimid have been confirmed in Canada by Apotex and Sandoz.

Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.

Sandoz has kicked off what promises to be a busy second half of 2021 in terms of launches for the Novartis subsidiary, introducing the first US generic of the Feraheme feumoxytol injectable treatment for iron deficiency anemia.

Biosimilar interchangeability is a hot topic in the US, with the first FDA decision on a formal interchangeability designation expected this month. But across the industry, views differ dramatically on the desirability and likely impact of this additional standard to biosimilarity.